Compare Synopsys, Inc. (SNPS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Zoetis Inc — how do they compare? Synopsys, Inc. trades at $509.64 (market cap $95.39B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Synopsys, Inc. is far larger — about 3.2× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 71 Days and Zoetis Inc for 70 Days on average.
| SNPS | ZTS | |
|---|---|---|
Market Cap | $95.39B | $30.20B |
Volume | 3,374,903 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $534.56 | $147.53 |
52-Week Low | $367.70 | $69.09 |
Typical Hold Time | 71 Days | 70 Days |
Enterprise Value | $102.62B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) stock trades at $505.76, up 0.61% today, near its 52-week high. The technical picture is bullish with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, the company reported strong quarterly earnings beats and robust revenue growth, driven by AI partnerships with OpenAI and Amazon. Analyst sentiment is overwhelmingly positive with a 93% buy rating and a consensus price target of $572.54, indicating significant upside potential.
The outlook for SNPS is highly favorable, supported by AI-driven demand for chip design software and strategic acquisitions like Ansys. Key risks include high valuation multiples and integration challenges from recent deals. Investors should focus on execution of growth initiatives and monitor competitive pressures in the semiconductor design software market.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
